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Peritoneal dialysis (PD) has been proposed as a therapeutic
option for patients with end-stage renal disease and
associated congestive heart failure (CHF). Here, we compare
mortality risks in these patients by dialysis modality by
including all patients who started planned chronic dialysis
with associated congestive heart failure and were prospectively
enrolled in the French REIN Registry. Survival was compared
between 933 PD and 3468 hemodialysis (HD) patients using
a Kaplan–Meier model, Cox regression, and propensity score
analysis. The patients were followed from their first dialysis
session and stratified by modality at day 90 or last modality
if death occurred prior. There was a significant difference
in the median survival time of 20.4 months in the PD group
and 36.7 months in the HD group (hazard ratio, 1.55).
After correction for confounders, the adjusted hazard ratio
for death in PD compared to the HD patients remained
significant at 1.48. Subgroup analyses showed that the
results were not changed with regard to the New York
Heart Association stage, age strata, or estimated glomerular
filtration rate strata at first renal replacement therapy.
The use of propensity score did not change results (adjusted
hazard ratio, 1.55). Thus, mortality risk was higher with
PD than with HD among incident patients with end-stage
renal disease and congestive heart failure. These results
may help guide clinical decisions and also highlight the
need for randomized clinical trials.
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Congestive heart failure (CHF) and chronic kidney disease
share a large number of risk factors and pathological
pathways, including activation of the renin–angiotensin–
aldosterone system, and have a causal relationship. In regis-
tries, prevalence of CHF among new end-stage renal disease
(ESRD) patients was about 25% in France and 35% in the
United States, and CHF was the main cardiovascular comor-
bidity at dialysis initiation.1,2 CHF was associated with poor
survival in ESRD patients, with a 25–35% mortality risk
excess as compared with non-CHF patients.3–6
Peritoneal dialysis (PD) has been proposed as a thera-
peutic option for management of refractory volume overload
because this renal replacement therapy (RRT) modality is
characterized by a continuous removal of extracellular fluid
and the absence of an arteriovenous access that may exacer-
bate signs of heart failure.7–13 In France, ESRD patients with
CHF were more likely to be initially treated with PD than
non-CHF populations: 17% versus 13%.1,14
Nevertheless, RRT modality choice—hemodialysis (HD)
or PD—for ESRD patients with CHF remained controver-
sial.14 Greater preservation of residual renal function (RRF),
continuous ultrafiltration with better hemodynamic stability,
improved clearance of medium-sized molecules, better
control of natremia, and improved systemic inflammatory
state were noted with PD treatment.7–13,15,16 HD was
associated with better control of sodium and water balance,
and better atherogenic lipid serum profile.17,18
Ideal tool for dialysis modality comparisons would be a
randomized, controlled trial. Previous attempts at such trials
were complicated by lack of statistical power and poor
recruitment.19,20 Without trial evidence, large observational
studies were of value to investigate mortality risks associated
with dialysis modalities.21
One observational study focused on survival comparisons
between RRT modalities in ESRD patients with CHF: in the
US, Stack et al.3 showed that mortality risks were signifi-
cantly higher for PD than for HD patients. Nevertheless,
follow-up was short (2 years). Recruitment was performed
from 1991 to 1997, before the use of low glucose degradation
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product solutions and icodextrin.15 Using recent data from
the French Renal Epidemiology and Information Network
(REIN) Registry, our aim was to update outcome comparison
between HD and PD in ESRD patients with CHF. All patients
with CHF who began RRT on a planned first dialysis session
were included.
RESULTS
Study population and validation of selection criteria
From 2002 to 2008, 7003 ESRD patients with associated CHF
began RRT in the French regions included in the REIN Registry.
After exclusion of patients with an unplanned first dialysis
session, 4401 (62.8%) were included in the study for analyses.
A validation study for unplanned first dialysis session
and CHF variables was conducted among a subset of 444
incident ESRD patients both registered in the REIN Registry
and the LSCAL (Lyon Sud and CALYDIAL (Centre Associatif
Lyonnais de Dialyse)) cohort.
In the REIN Registry, 5% of the patients with unplanned
first dialysis session were misclassified (patients registered
as having planned first dialysis session although they had
an unplanned one). Less than 5% of the patients with
planned first session were misclassified (patients registered
as having unplanned first dialysis session, although they had
a planned one).
Less than 3% of incident ESRD patients without CHF
were misclassified (patients registered as having CHF,
although they had no clinical evidence of CHF). Among
them, 62% started dialysis in an emergency basis and were
excluded from the present study. Residual misclassification
was therefore 1.1%. Among patients with CHF, o3% was
also misclassified (patients registered as not having CHF,
although they had clinical evidence of CHF).
Baseline characteristics of the study cohort
Baseline patient characteristics stratified by dialysis modality
at day 90 or last dialysis modality if death occurred before
day 90 are shown in Table 1: HD was the RRT modality in
3468 patients (78.8%, HD90 group) and PD in 933 (21.2%,
PD90 group), as compared with 92.9% and 7.1%, respectively,
in the unplanned first dialysis session subgroup we excluded
(Po0.0001).
In these patients who had planned first dialysis session,
10.4% began on HD with central venous catheter (CVC)
among PD90 patients, when 38.2% began on CVC among
HD90 patients (Po0.001).
PD90 group was older in average but had fewer comorbid
conditions compared with the HD90 group. Type 2 diabetes,
peripheral vascular disease (PVD), stage III–IV PVD, and
current cigarette smoking were less common among PD90
Table 1 | Baseline patient characteristics by dialysis modality at day 90 after first renal replacement therapy in incident ESRD
patients with associated CHF (French REIN Registry, 2002–2008)
Whole cohort (n=4401) HD90 (n=3468) (78.8%) PD90 (n=933) (21.2%) P-value
Age at first RRT (mean years±s.d.) 73.2±11.5 72.5±11.6 75.9±10.1 o0.001
Gender (female) 1450 32.9% 1109 32.0% 341 36.5% 0.008
CHF (NYHA III–IV) 1213 27.6% 898 25.9% 315 33.8% o0.001
CVC at dialysis initiation 1421 32.3% 1324 38.2% 97 10.4% o0.001
Primary renal disease o0.001
Diabetes 1191 27.1% 970 28% 221 23.7%
Renal vascular disease 1662 37.8% 1276 36.8% 386 41.4%
Glomerular nephropathy 286 6.5% 237 6.8% 49 5.3%
Polycystic 101 2.3% 89 2.6% 12 1.3%
Other 1161 26.4% 896 25.9% 265 28.4%
Comorbidities
Type 1 diabetes 151 3.4% 121 3.5% 30 3.2% 0.47
Type 2 diabetes 1920 43.6% 1541 44.4% 379 40.6% o0.001
CADa 1899 43.4% 1475 42.8% 424 45.9% 0.088
PVDb 1632 37.8% 1315 38.6% 317 34.9% 0.040
PVD Leriche III–IV 515 12.2% 437 13.1% 78 8.7% 0.001
Cerebrovascular disease 582 13.3% 445 12.9% 137 14.9% 0.120
Chronic lung disease 779 17.9% 605 17.6% 174 18.9% 0.342
Liver cirrhosis 85 1.9% 66 1.9% 19 2.1% 0.759
Current cigarette smoking 352 9.8% 297 10.3% 55 7.8% 0.039
Behavior disturbances 155 3.6% 119 3.5% 36 3.9% 0.523
eGFR (MDRD equation)c 10.9±6.3 10.3±5.3 13.2±8.5 o0.001
eGFRX15ml/min per 1.73m2 (MDRD equation)c 581 16.4% 363 13.2% 218 27.8% o0.001
Abbreviations: CAD, coronary artery disease; CHF, congestive heart failure; CVC, central venous catheter; eGFR, estimated glomerular filtration rate; ESRD, end-stage renal
disease; HD, hemodialysis; MDRD, Modification of the Diet in Renal Disease; NYHA, New York Health Association; PD, peritoneal dialysis; PVD, peripheral vascular disease;
REIN, Renal Epidemiology and Information Network; RRT, renal replacement therapy.
aIncludes a history of coronary artery disease, angina pectoris, myocardial infarction, coronary artery bypass surgery, angioplasty, or abnormal angiography.
bIncludes a history of peripheral vascular disease, amputation, intermittent claudication, or absent pulses.
cAvailable in 3537 patients (80.4%).
Italic values denote that results are statistically significant.
Kidney International (2011) 80, 970–977 971
F Sens et al.: ESRD, heart failure, and dialysis modality o r ig ina l a r t i c l e
patients, whereas female gender, New York Heart Association
(NYHA) stage III–IV CHF, and coronary artery disease were
more common. Renal biopsy was performed in less than 10%
of the patients in this cohort. Renal vascular disease was the
main cause of ESRD in both groups.
At first dialysis session, estimated glomerular filtration
rate (eGFR) using the abbreviated Modification of the Diet in
Renal Disease (MDRD) equation was available in 3537
patients (80.4%). On average, eGFR was 3 ml/min per
1.73 m2 higher in PD90 than in HD90 patients (Po0.001).
Rate of patients starting dialysis with an eGFRX15 ml/min
per 1.73 m2 was twofold higher in the PD90 group than in the
HD90 group.
After day 90, 22 (0.6%) HD90 patients switched to PD at a
median time of 4.3 months after day 90. Among PD90
patients, 98 (10.5%) switched to HD at a median time of 12.4
months after day 90.
A total of 141 (3.2%) patients had a renal transplant
during follow-up: 120 (3.5%) among HD90 patients, at an
average time of 21.7 months after first RRT; and 21 (2.3%)
among PD90 patients, at an average time of 24.9 months
(P¼ 0.063).
Univariate survival analysis
In univariate analysis, survival from first dialysis session was
lower in PD90 patients (Figure 1). Median survival time was
20.4 (18.2–22.6) months in PD90 group and 36.7 (34.3–39.1)
months in HD90 group. Crude hazard ratio (HR) for death in
PD90 versus HD90 patients was 1.55 (1.40–1.72), Po0.0001
(log-rank test).
Cause of death
Causes of death by day 90 dialysis modality are shown in
Table 2. Rates of cardiovascular cause of death were
significantly higher in PD90 patients than in HD90 patients,
whereas rates of cancer and unknown cause of death were
lower in PD90 patients.
Multivariate survival analysis
After adjustment for confounders (Table 3), multivariate
survival analysis from first dialysis session showed that PD90
patients experienced a significantly higher mortality risk than
HD90 patients: adjusted HR (aHR) for death in PD90 versus
HD90 patients was 1.48 (1.33–1.65), Po0.0001. In this
cohort, other variables significantly associated with death
were age, NYHA stage III–IV CHF, CVC use at first dialysis
session, PVD, liver cirrhosis, and behavior disturbance
(Table 3).
Results were not changed by stratification on dialysis
modality at first dialysis session (aHR: 1.48 (1.32–1.66),
Po0.0001) or when patients were censored at RRT modality
switches (1.42 (1.26–1.59), Po0.0001). When patients who
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Figure 1 |Non-adjusted survival and 95% confidence interval
by day 90 dialysis modality in incident end-stage renal
disease patients with associated congestive heart failure
(French REIN Registry, 2002–2008, Kaplan–Meier, Po0.0001).
HD, hemodialysis; PD, peritoneal dialysis.
Table 2 | Cause of death (number, %) by dialysis modality
in incident ESRD patients with associated CHF (French REIN
Registry, 2002–2008)
HD90 (n=1173) PD90 (n=490) P-value
a
Cardiovascular cause 410 (35.0%) 197 (40.2%) 0.04
Sudden death 210 (17.9%) 75 (15.3%) 0.20
Infectious disease 114 (9.7%) 49 (10.0%) 0.86
Cancer 82 (7.0%) 20 (4.1%) 0.02
Other known 266 (22.7%) 125 (25.5%) 0.21
Unknown 91 (7.7%) 24 (4.9%) 0.04
Abbreviations: CHF, congestive heart failure; ESRD, end-stage renal disease; HD,
hemodialysis; PD, peritoneal dialysis; REIN, Renal Epidemiology and Information
Network.
a2 2 w2-test for each cause of death.
Overall: P=0.015 between groups.
Table 3 |Multivariate analysis in incident ESRD patients
with associated CHF (French REIN Registry, 2002–2008,
Cox regression)
Adjusted
hazard ratio 95% CI P-value
PD90 vs HD90 1.48 1.33–1.65 o0.0001
Age at first RRT (+1 year) 1.04 1.03–1.05 o0.0001
Female vs male 1.02 0.92–1.13 0.70
CHF NYHA III–IV vs NYHA I–II 1.52 1.38–1.68 o0.0001
CVC use at dialysis initiation 1.35 1.22–1.49 o0.0001
Type 1 diabetes 1.11 0.98–1.27 0.11
Type 2 diabetes 1.00 0.95–1.05 0.99
CAD 1.09 0.99–1.20 0.09
PVD 1.23 1.11–1.35 o0.0001
Cerebrovascular disease 1.11 0.98–1.27 0.10
Chronic lung disease 1.09 0.97–1.22 0.17
Liver cirrhosis 1.89 1.40–2.54 o0.0001
Current cigarette smoking 1.05 0.88–1.26 0.56
Behavior disturbances 1.81 1.45–2.25 o0.0001
Abbreviations: CAD, coronary artery disease; CHF, congestive heart failure; CI,
confidence interval; CVC, central venous catheter; ESRD, end-stage renal disease; HD,
hemodialysis; NYHA: New York Health Association; PD, peritoneal dialysis; PVD,
peripheral vascular disease; REIN, Renal Epidemiology and Information Network;
RRT, renal replacement therapy.
Italic values denote that results are statistically significant.
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survival analysis from day 90 showed that aHR for death in
PD versus HD was 1.57 (1.39–1.78; Po0.0001).
Subgroup analyses
We did not find any significant interaction between RRT
modality and other variables, especially age. When stratified
on age (cutoff 75 years) and on diabetes, results were not
changed (Table 4).
In patients with known eGFR at first dialysis session
(n¼ 3537, 80.4%), there was no significant interaction between
RRT modality and eGFR stages (o5, 5–15, and 415 ml/min
per 1.73 m2; P¼ 0.12). In patients with eGFRo15 ml/min per
1.73 m2 (n¼ 2956) and with eGFRX15 ml/min per 1.73 m2
(n¼ 581), aHR for death in PD90 versus HD90 patients were
1.47 (1.28–1.70; Po0.0001) and 1.34 (1.03–1.74; P¼ 0.03),
respectively. Results did not change when analysis was
adjusted on eGFR modeled as a continuous variable (aHR:
1.43 (1.26–1.62), Po0.0001) or as a categorical variable
(o5, 5–15, and 415 ml/min per 1.73 m2; aHR: 1.44
(1.27–1.63), Po0.0001).
Interaction between RRT modality and NYHA stage was
not significant (P¼ 0.86). In NYHA stage I–II CHF patients
(n¼ 3188), aHR for death in PD90 versus HD90 patients was
1.51 (1.32–1.71), Po0.0001. In NYHA stage III–IV CHF
patients (n¼ 1213), aHR for death in PD90 versus HD90
patients was 1.43 (1.19–1.73), Po0.0001.
Propensity score analysis
Owing to the not random allocation of dialysis modality, we
performed a propensity score (PS) analysis. We estimated
each patient’s PS to be treated with PD and included it in Cox
regression as a stratification variable or as an adjustment
variable. These analyses did not change results (Table 5):
when Cox regression was stratified for PS quintiles, aHR for
death was 1.55 (1.36–1.77), Po0.0001; when Cox regression
was adjusted on PS alone, aHR was 1.55 (1.37–1.77),
Po0.0001.
DISCUSSION
In this prospective, recent, large, non-selected and popula-
tion-based cohort from the REIN Registry, mortality risk
associated with PD was significantly higher than the one
associated with HD. Results were consistent among patient
subgroups by eGFR at dialysis onset, NYHA CHF stages, age
or diabetes status, by origins of follow-up, or by statistical
methods.
These results in France were in line with results showed in
the United States by Stack et al.3 in a 1991–1997 cohort built
before approved use of low glucose degradation product and
icodextrin for PD patients.15 In 35,285 ESRD patients with
associated CHF, aHR for death in PD versus HD patients
were 1.30 (1.20–1.41) in diabetics and 1.24 (1.14–1.35) in
non-diabetics.3 Analyses were only conducted in the first
2 years after dialysis initiation and did not take into account
CHF stage and eGFR at dialysis initiation. Compared with the
French cohort, patients were younger (median age 64 years)
and had more comorbid conditions, such as coronary artery
disease, PVD, cerebrovascular disease, and diabetes. As com-
pared with the United States,3 rate of diabetes-related ESRD
was lower because rates of diabetes mellitus remained lower
in French population. Renal vascular disease was the main
cause for ESRD, as expected in this cohort selected on
CHF status with an average age of 72 years. As already
described in the United States,22 and in contrast to France,
CHF patients in Stack’s study were less likely to be treated
with PD than non-CHF patients (10.5% versus 14.5%). Such
differences between countries could be explained in part by
differences in PD health-care network coverage between
France and the United States, improvement of dialysis
techniques over decades, and ability to maintain very old
people on PD in France with home-care nurses.23
Although data on icodextrin use was not available in the
REIN Registry, data from the French Peritoneal Dialysis
Registry indicated that more than 60% of the French PD
patients had icodextrin in their programs during the study
period (http://www.rdplf.org).23 Considering CHF patients
on PD who need high ultrafiltration level, we may consider
that this overall rate was the lower estimation of the rate for
icodextrin use in the studied population.7–13 Nevertheless,
availability of icodextrin in the French cohort did not change
results in comparison with Stack et al. results.3
CHF diagnosis was performed by the patient’s referent
nephrologist and registered in the REIN database, as in other
population-based registries1–3,23 or prospective studies.24,25
CHF is a clinical syndrome as defined by the American
College of Cardiology Foundation and the American Heart
Association Task Force.26 Neither echocardiography nor bio-
logical markers are validated for diagnosis of CHF, espe-
cially in ESRD population.27,28 This definition is therefore in
Table 4 |Multivariate analysis in incident ESRD patients
with associated CHF (French REIN Registry, 2002–2008,
Cox regression), stratified by age (cutoff: 75 years)
and diabetes status (all P-values for interaction 40.05)
Group Number Adjusted HR 95% CI P-value
Ageo75 years, no diabetes 987 1.89 1.42–2.52 o0.001
Ageo75 years, diabetes 1108 1.49 1.15–1.94 0.002
AgeX75 years, no diabetes 1343 1.46 1.22–1.74 o0.001
AgeX75 years, diabetes 963 1.45 1.17–1.80 0.001
Abbreviations: CHF, congestive heart failure; CI, confidence interval; ESRD, end-stage
renal disease; HR, hazard ratio; REIN, Renal Epidemiology and Information Network.
Table 5 |Multivariate analysis in incident ESRD patients
with associated CHF using PS analysis (French REIN Registry,
2002–2008, Cox regression)
Adjusted
HR 95% CI P-value
Cox regression stratified for PS quintiles 1.55 1.36–1.77 o0.0001
Cox regression adjusted for PS alone 1.55 1.37–1.77 o0.0001
Abbreviations: CHF, congestive heart failure; CI, confidence interval; ESRD, end-stage
renal disease; HR, hazard ratio; PS, propensity score; REIN, Renal Epidemiology and
Information Network.
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agreement with CHF criterion in our registry. Furthermore,
the French REIN Registry has explicit quality control proce-
dures (http://www.agence-biomedecine.fr/uploads/document/
Rapport-REIN-2008-couv.pdf),1,29 in line with international
guidelines on epidemiology and on patient registry regarding
condition notification. Given the results of the validation
study that we performed among the LSCAL cohort patients
(misclassification o3%), all these made good the veracity
of diagnosis of CHF in patients we included in the present
study, and the veracity of diagnosis of normal heart function
in patients we excluded. At least to limit the impact of
CHF diagnosis bias, we performed subgroup analysis in
patients registered with NYHA CHF stages III–IV. In these
patients, diagnosis bias should be considered even lower, and
the result of the PD versus HD outcome comparison was
not changed.
The present study does not provide evidence for
mechanism of this increased mortality risk among PD
patients, but we can notice that rates of cardiovascular cause
of death were higher in PD that in HD patients. There are,
however, several hypothesis: fluid removal was less predict-
able and could be inadequate in PD patients;30,31 PD patients
had a more atherogenic serum-lipid profile18 that could be
associated with a higher cardiovascular mortality; PD
patients have an increased risk of infectious death, largely
accounted for by bacterial or fungal peritonitis,32 but we did
not find here a difference in the rates of infectious causes of
death by RRT modality group; finally, increased risk may be
explained by differences in medical monitoring and pre-
scription adaptation related to home care in PD patients.33
We can hypothesize that some of these patients had CHF
refractory to conventional therapy with indication of
extracorporeal ultrafiltration. As described previously,7–13
we therefore cannot exclude a selection bias that led
preferentially these higher-risk patients to be treated on
PD: in this French cohort, patients on PD were older and had
actually higher rates of NYHA stage III–IV CHF and higher
eGFR at baseline compared with HD patients. We did not
find any interaction between dialysis modality and these
variables. PD was associated with a significant higher
mortality risk as compared with HD in NYHA stage III–IV
patients, in patients with eGFRX15 ml/min per 1.73 m2, or
in older patients. No interaction with any other available
variables was found. Nevertheless, despite adjustment on
several confounders, selection bias cannot be excluded in this
observational study and these results deserved randomized
trial outcome comparison.
We excluded CHF patients with unplanned first dialysis
session. In this group, only 7.1% were treated by PD. There
was a selection bias in favor of HD: patients who began
dialysis on HD because of a life-threatening circumstance did
not change for PD. This led to questionable PD and HD
comparison in this group.34–36 Moreover, we described
previously that pulmonary fluid overload was the cause of
dialysis emergency start in 80% of the cases, regardless of
CHF comorbidity status.36 The validation study confirmed
the potential misclassification bias: two-thirds of patients
misclassified as having CHF had begun dialysis in emergency.
Avoiding this bias was the rationale for excluding patients
with unplanned first dialysis session from the present study.
Nevertheless, when these patients were included in analysis,
main results did not change (n¼ 7003, aHR for death in PD
versus HD: 1.31 (1.19–1.43), Po0.0001).
Despite these measures, we cannot exclude the fact that
some patients classified as having CHF NYHA stages I–II had
pulmonary fluid overload due to ESRD without heart
involvement. However, we can hypothesize that patients
with eGFRX15 ml/min per 1.73 m2—indicating that RRT
was started for refractory CHF—and patients with NYHA
stages III–IV at baseline had actual CHF. In these subgroups,
as in the whole cohort, adjusted mortality risk associated
with PD remained significantly higher than that in HD
patients.
In this cohort, it was noteworthy that 10.4% of PD90
patients who had planned first dialysis began dialysis on HD
with CVC. It has been reported that rates of PD catheter early
dysfunction and leakage were about 10%,37–39 explaining that
planned PD patients may start dialysis on HD with CVC.
As in a previous study of mortality in ESRD pati-
ents,3,19,24,25,40–45 age, NYHA stage III–IV CHF, CVC use
at first dialysis session, PVD, liver cirrhosis, and behavior
disturbance were associated with death. In this CHF patient
cohort, diabetes was not associated with death, probably
because of selection of patients with very high mortality risks.
Overall median survival was lower than 3 years.
Nevertheless, because selection bias and confounding bias
may distort the true mortality risks associated with PD and
HD, results of this study, as the previous ones,3,19,24,25,40–45
should be interpreted cautiously.
As in other countries, RRT modality choice is based on
patient’s clinical state and patient’s choice, largely influenced
by physician practice, health-care organization, or cost
reimbursement by public or private insurances. We tried to
control selection bias by excluding patients with unplanned
first dialysis session and by including major confounding
factors in analyses. Nevertheless, this bias could only be
controlled by randomized trial. Poor recruitment in previous
randomized studies on this topic unfortunately limits the
practicality of such projects.19,20
Furthermore, our study, similar to a previous study by
Stack et al.,3 did not take into account potential confounding
factors as dialysis dose, nutritional condition, inflammatory
status, or B-type natriuretic peptide.
In conclusion, this study in the French cohort of incident
ESRD patients with associated CHF who started planned
chronic RRT showed that mortality risk associated with PD
was higher than mortality risk in HD. Worse survival among
PD patients was noted in all subgroups, especially by eGFR
and NYHA CHF stages at baseline. Beyond difficulties,19,20
this raised the issue of a randomized controlled trial in CHF
patients without contraindication for both dialysis modalities
to confirm or invalidate this result.
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MATERIALS AND METHODS
Study design
With data from the study published by Stack et al.3 and using
approach of Schoenfeld and Richter,46 we were able to calculate
sample size needed in the present study. When HR for death in PD
patients versus HD patients was 1.24, a-risk was 0.05, study power
was 0.9, median survival in HD group was 30 months, and
proportion of PD-treated patients was 15%, study sample had to
include 2578 patients.
Patients
We included all patients aged 18 years and above with a history of
CHF at first RRT who began planned chronic dialysis from 1 January
2002 to 31 December 2008 in France and were prospectively recorded
in the French REIN Registry (http://www.agence-biomedecine.fr/
uploads/document/Rapport-REIN-2008-couv.pdf).1,29 We excluded
patients without CHF at first dialysis session, patients who began
dialysis in emergency (unplanned first dialysis session), and patients
who had preemptive renal transplantation. Patients were followed
up until renal transplantation, death, or 31 December 2008.
The French REIN Registry began in 2002 and was progressively
expanding to include all ESRD patients on RRT living in France. All
new patients were reported from first day of RRT, except patients
with diagnosis of acute renal failure who were excluded. Details of
its organizational principles and quality control have been described
elsewhere.29 The registry currently covers 20 regions and 86% of
the French population (http://www.agence-biomedecine.fr/uploads/
document/Rapport-REIN-2008-couv.pdf).
Data
Baseline information at dialysis initiation included age, gender,
weight, primary renal disease, comorbidities, smoking status, beha-
vior disturbance, use of CVC at first dialysis session, and serum
creatinine.
CHF was defined on the basis of the presence or absence of this
condition on the REIN Registry medical evidence form filled by
referent Nephrologists in dialysis units. CHF was staged with the
New York Health Association (NYHA) scale (I–II and III–IV). When
CHF stage was not registered (o10% of the cases), we allocated
NYHA stages I–II to this variable.
Unplanned dialysis was defined as any first dialysis that begun on
an emergency basis, that is, in life-threatening circumstances
requiring dialysis within 24 h (http://www.agence-biomedecine.fr/
uploads/document/Rapport-REIN-2008-couv.pdf).1,29,36,42
Initial dialysis modality was defined as the modality at day 90
after first dialysis (HD90 group and PD90 group), or the one at
dialysis initiation if death occurred before the 90th day. Secondary
analyses were reprocessed stratifying patients on RRT modality at
first dialysis.
Other comorbid conditions included history of type 1 and type 2
diabetes, coronary artery disease (defined as a history of prior
angina pectoris, myocardial infarction, or coronary artery bypass
surgery or angioplasty), PVD (including a history of amputation,
intermittent claudication, or absent arterial pulses using Leriche
classification stages I–IV), cerebrovascular disease, chronic lung
disease, and liver cirrhosis.
Baseline laboratory measurements included serum creatinine for
more than 80% of the present cohort. eGFR was assessed by the
simplified MDRD formula.47
Dates of renal transplantation and/or death were known until 31
December 2008.
Any switches in treatment modality were recorded with date
until 31 December 2008.
Validation study
EV conducted a validation study to assess the potential misclassi-
fication for CHF and unplanned first dialysis session variables.
EV reviewed and compared the files of 444 patients both included
in the data set of incident dialysis patients at the Department
of Nephrology of the Centre Hospitalier Lyon-Sud (Academic
Hospital) and CALYDIAL (non for profit dialysis association)
used in previous studies (LSCAL cohort)36,48,49 and in the REIN
Registry data set. We assessed patient misclassification rates for
these variables.
Statistical analysis
When appropriate, univariate comparisons were made using w2-test
or Fisher’s exact test for categorical variables, and using Student’s
t-test for continuous variables.
Patient survival times were compared between HD and PD
patients from the first dialysis. Patients were right censored at renal
transplantation date if this event occurred during follow-up. They
were not censored in main analyses at RRT modality switches.
Times to death were examined with Kaplan–Meier model for
univariate analysis and Cox regression for multivariate analysis.
Validity of the Cox proportional hazard assumption was checked by
tests based on Schoenfeld residuals.50 The origin of the survival time
was the day of the first dialysis session. The end of the survival time
was date of death, or 31 December 2008 if patient survived to this date,
or date of renal transplantation. Secondary analyses were reprocessed
using day 90 as origin of the survival time in patients who survived
the 90th day, and censoring patients at RRT modality switches.
Models were adjusted for age, gender, use of CVC at dialysis
initiation, and comorbidities at first RRT. Variables were introduced
step by step in the model with backward and forward entrance. We
did not add primary renal disease in multivariate Cox regression
because correlations between renal diseases and cardiovascular/
diabetes comorbid conditions.
We performed subgroup analyses to investigate the robust-
ness of study results and check their reliability. We compared CHF
patients mortality according to their dialysis modality, separately for
patients with NYHA stages I–II and III–IV, as well as GFR at dialysis
initiation o15 and 415 ml/min. We compared outcome by age
(cutoff 75 years, median age) and diabetes status. We checked for
other interactions by entering interaction terms in Cox regression. If
other significant interactions were found, we performed stratified
survival analysis.
To take into account differences in the probability for each patient
to be treated by HD or PD, we implemented a PS method.24,51 Each
patient’s PS, that is, the probability of being treated with PD at day 90,
was estimated by using logistic regression. Eighteen pretreatment
covariates likely to explain PD allocation at day 90 were introduced in
the model: age, gender, use of CVC at dialysis initiation, CHF NYHA
stage, all comorbidities at first RRT, cigarette smoking status, and
behavior disturbance. We built thereafter two multivariate Cox
proportional hazards models: the first was adjusted on the same
covariates as in our main model, and stratified for PS quintiles,
transformed into dummy variables on the basis of the predicted
probabilities; the second was adjusted for PSs only.
A two-sided P-valueo0.05 was considered statistically significant.
All statistical analyses were performed with S-PLUS 6.2 Software
Professional Release 2 (1988–2003 Insightful, Seattle, WA).
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